Nyxoah SA was listed on the Nasdaq exchange, and Cantor Fitzgerald reiterated an overweight rating on the company.
2 reports, 2 independent
Updated Oct 19
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nyxoah SA was listed on the Nasdaq exchange, and Cantor Fitzgerald reiterated an overweight rating on the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Nyxoah SA submitted a PMA supplement to the FDA after listing on Nasdaq.1 source
Nyxoah SA listed on Nasdaq with an overweight rating from Cantor Fitzgerald.1 source
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald restated an overweight rating for MoonLake Immunotherapeutics, which trades on Nasdaq, with data provided by MarketBeat.
- Cantor Fitzgerald reiterated an overweight rating for IREN on November 3, 2026.
- Cantor Fitzgerald and Citigroup restated positive rating upgrades for Sagimet Biosciences.
- Barclays dropped its target price and set an underweight rating, while Cantor Fitzgerald also issued an underweight rating for Polestar.
- Multiple financial firms, including Raymond James, Wells Fargo, UBS, Cantor Fitzgerald, and KeyCorp, issued rating updates and target price changes on November 2, 2026.